Epirubicin News and Research

RSS

A combination of chemotherapy drugs could double survival rates for pancreatic cancer

Pancreatic cancer has a poor prognosis. More than 80% of patients present with advanced disease at diagnosis, and mortality is high. A single chemotherapy drug, gemcitabine, is regarded as the standard treatment, but it has lead to a 1-year overall survival of only 17—28% in clinical trials.

9 May 2005

Herceptin - more powerful treatment for patients with HER-2-positive breast cancer

A new use of the drug Herceptin appears to offer a much more powerful treatment advantage than expected for patients with HER-2-positive breast cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.

29 Mar 2005

Herceptin shows real promise in treatment of HER-2 positive breast disease

According to a study conducted at The University of Texas M. D. Anderson Cancer Center, more than twice as many women with early stage, HER-2 positive breast disease who received Herceptin as part of their pre-surgery chemotherapy had their tumors completely disappear compared to like patients who received only chemotherapy.

7 Jun 2004

First patient dosed with Tesmilifene in pivotal breast cancer study

YM BioSciences Inc., the cancer drug development company, today announced that the first patient has been dosed in its 700 patient Phase III registration trial.

31 Mar 2004